Sign In
Buy EKSO
$4.16
-0.330 (-7.35%)
At Close: Nov 17, 2025
Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
08:00am, Wednesday, 29'th Oct 2025
SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announce
Ekso Bionics (EKSO) Reports Q3 Loss, Beats Revenue Estimates
06:16pm, Tuesday, 28'th Oct 2025
Ekso Bionics (EKSO) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to a loss of $1.5 per share a year ago.
Ekso Bionics Reports Third Quarter 2025 Financial Results
04:05pm, Tuesday, 28'th Oct 2025
SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and
Ekso Bionics (EKSO) Upgraded to Buy: Here's What You Should Know
01:00pm, Friday, 26'th Sep 2025
Ekso Bionics (EKSO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ekso Bionics (EKSO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Wednesday, 13'th Aug 2025
Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among W
Ekso Bionics Holdings, Inc. (EKSO) Q2 2025 Earnings Call Transcript
06:20pm, Monday, 28'th Jul 2025
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants Jerome Wong - CFO & Corporate Secretary Scott G. Davis - CEO & Director Stephe
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
06:16pm, Monday, 28'th Jul 2025
Ekso Bionics (EKSO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.95 per share a year ago.
Ekso Revenue Falls 58 Percent in Q2
04:20pm, Monday, 28'th Jul 2025
Ekso Revenue Falls 58 Percent in Q2
Ekso Bionics Reports Second Quarter 2025 Financial Results
04:05pm, Monday, 28'th Jul 2025
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and
Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
04:45pm, Monday, 21'st Jul 2025
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today
Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
08:00am, Friday, 18'th Jul 2025
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
07:30am, Wednesday, 18'th Jun 2025
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company an
Ekso Bionics Announces New Effective Date of Reverse Stock Split
04:30pm, Wednesday, 21'st May 2025
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced
Ekso Bionics Announces Reverse Stock Split
04:30pm, Monday, 19'th May 2025
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced
Ekso Bionics Accepted into NVIDIA Connect Program
07:45am, Thursday, 15'th May 2025
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation
